Market capitalization | €1.67b |
Enterprise Value | €-1.75b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 3.32 |
EV/Sales (TTM) EV/Sales | -3.21 |
P/S ratio (TTM) P/S ratio | 3.07 |
P/B ratio (TTM) P/B ratio | 0.58 |
Revenue growth (TTM) Revenue growth | -5.75% |
Revenue (TTM) Revenue | €543.97m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
14 Analysts have issued a Galapagos forecast:
14 Analysts have issued a Galapagos forecast:
Sep '23 |
+/-
%
|
||
Revenue | 544 544 |
6%
6%
|
|
Gross Profit | 526 526 |
1%
1%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -209 -209 |
22%
22%
|
Net Profit | -153 -153 |
2,848%
2,848%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Paulus Stoffels |
Employees | 1,123 |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.